HomeCompareKLDI vs PFE

KLDI vs PFE: Dividend Comparison 2026

KLDI yields 40000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KLDI wins by $5.18024517379999e+22M in total portfolio value
10 years
KLDI
KLDI
● Live price
40000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.18024517379999e+22M
Annual income
$51,548,940,318,215,365,000,000,000,000.00
Full KLDI calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — KLDI vs PFE

📍 KLDI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKLDIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KLDI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KLDI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KLDI
Annual income on $10K today (after 15% tax)
$3,400,000.00/yr
After 10yr DRIP, annual income (after tax)
$43,816,599,270,483,060,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, KLDI beats the other by $43,816,599,270,483,060,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KLDI + PFE for your $10,000?

KLDI: 50%PFE: 50%
100% PFE50/50100% KLDI
Portfolio after 10yr
$2.590122586899995e+22M
Annual income
$25,774,470,159,107,683,000,000,000,000.00/yr
Blended yield
99.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

KLDI
No analyst data
Altman Z
-1.4
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KLDI buys
0
PFE buys
0
No recent congressional trades found for KLDI or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKLDIPFE
Forward yield40000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$5.18024517379999e+22M$49.6K
Annual income after 10y$51,548,940,318,215,365,000,000,000,000.00$26,258.71
Total dividends collected$5.178579568047658e+22M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KLDI vs PFE ($10,000, DRIP)

YearKLDI PortfolioKLDI Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$4,010,700$4,000,000.00$9,153$693.39+$4.00MKLDI
2$1,503,618,552$1,499,327,102.80$8,593$849.25+$1503.61MKLDI
3$526,936,342,129$525,327,470,278.19$8,336$1,066.78+$526936.33MKLDI
4$172,618,628,820,566$172,054,806,934,488.28$8,437$1,384.80+$172618628.81MKLDI
5$52,860,672,107,805,460$52,675,970,174,967,450.00$9,013$1,875.40+$52860672107.80MKLDI
6$15,132,132,379,588,594,000$15,075,571,460,433,242,000.00$10,306$2,680.72+$15132132379588.58MKLDI
7$4,049,462,878,006,525,600,000$4,033,271,496,360,366,000,000.00$12,820$4,101.38+$4049462878006525.50MKLDI
8$1,013,053,710,099,385,500,000,000$1,008,720,784,819,918,400,000,000.00$17,673$6,826.70+$1013053710099385472.00MKLDI
9$236,926,560,546,299,530,000,000,000$235,842,593,076,493,200,000,000,000.00$27,543$12,591.86+$236926560546299510784.00MKLDI
10$51,802,451,737,999,890,000,000,000,000$51,548,940,318,215,365,000,000,000,000.00$49,560$26,258.71+$5.18024517379999e+22MKLDI

KLDI vs PFE: Complete Analysis 2026

KLDIStock

KLDiscovery Inc. provides eDiscovery, information governance, and data recovery solutions to corporations, law firms, government agencies, and individual consumers worldwide. The company offers eDiscovery solutions, including Nebula Ecosystem, an information governance and eDiscovery platform, which helps to facilitate the identification, preservation, collection, processing, review, and exchange of electronically stored information (ESI); eDiscovery.com Review, a platform used to search, review and exchange ESI; and Relativity, a document review tool. It also provides KLD Analytics, which offers technology-assisted review tools for predictive coding, workflow, email threading, near-duplicate detection, and language identification; KLD Processing, a processing platform; technology enabled managed review services; digital forensics services; and information archiving services. In addition, the company offers advisory services, such as eDiscovery readiness and response solutions, including eDiscovery expert witness, custodian interviews, preservation and collection strategy, and legal hold solution; information governance solutions comprising Office 365 health check and legal hold process improvement; and data privacy solutions, including privacy compliance assessment and data breach risk mitigation. Further, it provides data recovery services; email recovery services; tape services comprising backup infrastructure migration and consolidation, legacy tape and data remediation, and recovery from physically-damaged and quickly-erased or partially-overwritten tapes; and data destruction services. Additionally, the company provides data recovery software, such as Ontrack EasyRecovery and Ontrack PowerControls. KLDiscovery Inc. was founded in 1985 and is headquartered in McLean, Virginia.

Full KLDI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this KLDI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KLDI vs SCHDKLDI vs JEPIKLDI vs OKLDI vs KOKLDI vs MAINKLDI vs JNJKLDI vs MRKKLDI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.